The world of medical research in Brazil has witnessed a remarkable development from the laboratories of the Federal University of Rio de Janeiro (UFRJ), where biologists led by Dr. Tatiana Sampaio have pioneered polilaminina, a novel therapeutic agent derived from placental laminin proteins. This innovation holds promise for revolutionizing treatment for acute spinal cord injuries, a condition that leaves thousands paralyzed annually in Brazil and globally. In a striking case, a Brazilian patient regained voluntary leg movement just 48 hours after receiving an experimental injection of polilaminina, sparking excitement within the higher education and research communities.
Spinal cord injuries represent a profound challenge in neurology, often resulting from trauma such as car accidents, falls, or violence. In Brazil, the Ministry of Health reports over 10,000 new cases each year, with complete lesions classified as ASIA A leading to permanent loss of motor and sensory function below the injury site. Traditional interventions focus on stabilization surgery, anti-inflammatory drugs, and rehabilitation, yet regeneration remains elusive due to the inhibitory environment created by scar tissue and disrupted neural pathways.
Origins of Polilaminina at UFRJ's Biomedical Research Hub
The story of polilaminina began nearly three decades ago at UFRJ's Instituto de Ciências Biomédicas (ICB-UFRJ), where Dr. Sampaio's Extracellular Matrix Biology Laboratory explored laminin's role in neural development. Laminin, a key extracellular matrix glycoprotein abundant in placentas, naturally supports axon growth during embryogenesis. By polymerizing laminin into a stable, scaffold-like structure—hence 'polilaminina'—researchers created a biomaterial that mimics the natural neural architecture, potentially bridging severed axons.
This serendipitous discovery stemmed from an unused vial of laminin in the lab, prompting tests that revealed its enhanced regenerative potential. Over years, UFRJ teams refined production using donated placentas, purifying and cross-linking the protein for surgical injectability. Preclinical studies in rats with acute contusion injuries demonstrated improved motor scores and axon sprouting, published in foundational papers from the group.
UFRJ's commitment to translational research shines here, with FAPERJ funding supporting early phases and royalties from patents licensed to Cristália laboratory exceeding R$3 million—the largest ever for the university. This financial boost underscores how university-industry partnerships in Brazil can propel biomedical innovation.
Preclinical Success: From Lab Models to Larger Animals
At UFRJ, rigorous animal testing laid the groundwork. In rat models of thoracic spinal cord contusion, polilaminina injections within hours post-injury significantly boosted Basso-Beattie-Bresnahan (BBB) locomotion scores, with treated animals achieving near-normal hindlimb function by week four. Histological analysis revealed reduced gliosis, preserved tissue integrity, and extensive axonal regrowth across the lesion site.
Advancing to chronic models, dogs with paraplegia from disc herniation received intramedullary injections. Remarkably, several regained ambulation within weeks, corroborated by veterinary neurologists. These findings, detailed in UFRJ collaborations with international labs, validated polilaminina's safety profile—no adverse immune responses or tumor formation observed.
Brazilian universities like UFRJ exemplify ethical preclinical research, adhering to CONCEA guidelines and emphasizing acute intervention windows (ideally 24-72 hours post-trauma) to preempt scarring.
The Pilot Human Study: Groundbreaking Early Results
In a landmark pilot at UFRJ-affiliated facilities, eight patients with complete acute SCI (ASIA A, thoracic/cervical) underwent surgery with polilaminina injection above and below the lesion. All received standard care plus the polymer within days of injury. Six regained voluntary motor control below the lesion—an unprecedented 75% rate versus historical 15% spontaneous recovery.
Patient outcomes varied: some achieved trunk stability, others partial ambulation. The study, a preprint from 2024, highlighted no serious treatment-related adverse events, though three deaths occurred from primary injuries. UFRJ's oversight committee approved protocol adjustments based on interim data, showcasing adaptive research in Brazilian academia.
Patient Stories: Hope from Brazilian University Research
Bruno Drummond, quadriplegic since 2018, exemplifies the potential. Post-injection, he regained foot movement, progressing to walking and stair-climbing—monitored by UFRJ teams. Similarly, young soldier Luiz Otávio Santos Nunes, treated in Mato Grosso do Sul via compassionate use, cut cake and wrote one month later.
Eduarda Atkinson, 23 from Santa Catarina, moved her leg days after application, crediting UFRJ's innovation. These cases, often court-mandated (~32 by early 2026), fuel demand but highlight ethical tensions in university-led compassionate access.
Anvisa Phase 1 Approval: Milestone for Brazilian Higher Ed
January 2026 marked history: Anvisa greenlit a Phase 1 safety trial for five volunteers (18-72 years, T2-T10 acute complete SCI, <72h post-trauma). Partnering UFRJ, Cristália, Hospital das Clínicas-USP, and Santa Casa São Paulo, it prioritizes acute cases for optimal efficacy. Expected completion end-2026, success paves Phase 2 efficacy trials.
This approval validates UFRJ's rigor, positioning Brazilian universities as SCI research leaders amid global efforts like stem cells or exoskeletons.
Ministry of Health announcementChallenges and Scientific Scrutiny in University Research
Critics note the pilot's small size, lack of controls, and acute-phase spontaneous recovery potential. Science.org highlighted hype risks, urging RCTs. UFRJ's Sampaio emphasizes preliminary nature, focusing Phase 1 safety.
Off-label deaths (three reported) underscore monitoring needs, denied as causal by Cristália. Brazilian higher ed navigates regulatory hurdles, balancing innovation with ethics via CEP/CONEP.
UFRJ's Role in Brazil's Biomedical Ecosystem
UFRJ exemplifies public university impact: ICB labs foster interdisciplinary teams, training PhDs in regenerative medicine. Royalties fund further research, while partnerships with Cristália scale production.
Brazil's unis like USP, Unicamp contribute rehab expertise, strengthening national SCI networks. This positions higher ed as biotech driver, addressing 250,000+ chronic cases.
Photo by Vladyslav Tobolenko on Unsplash
Implications for Higher Education and Research in Brazil
Polilaminina spotlights funding gaps: FAPERJ/CNPq vital, yet international comparisons show Brazil's R&D investment lags. Success could boost university patents, attracting global collaborators.
For students, it inspires neuroscience/medicine careers; UFRJ programs emphasize translational skills. Policymakers eye SUS integration, enhancing unis' societal role.
Future Outlook: Trials, Global Potential, and University Leadership
Phase 1 success could accelerate Phases 2/3, targeting 2028 registration. UFRJ eyes chronic SCI expansions, combining with neurostimulation.
As Brazilian higher ed advances, polilaminina symbolizes resilience—promising mobility restoration while exemplifying rigorous, ethical university research.